当前位置：
X-MOL 学术
›
Clin. Appl. Thromb. Hemost.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
ADAMTS13 Autoantibodies and Burden of Care in Immune Thrombotic Thrombocytopenic purpura: New Evidence and Future Implications
Clinical and Applied Thrombosis/Hemostasis ( IF 2.9 ) Pub Date : 2022-09-19 , DOI: 10.1177/10760296221125785 Cristina Dainese 1 , Federica Valeri 1 , Eleonora Pizzo 2 , Alessandra Valpreda 2 , Piera Sivera 3 , Barbara Montaruli 4 , Annamaria Porreca 5 , Massimo Massaia 6 , Benedetto Bruno 7 , Alessandra Borchiellini 1
Clinical and Applied Thrombosis/Hemostasis ( IF 2.9 ) Pub Date : 2022-09-19 , DOI: 10.1177/10760296221125785 Cristina Dainese 1 , Federica Valeri 1 , Eleonora Pizzo 2 , Alessandra Valpreda 2 , Piera Sivera 3 , Barbara Montaruli 4 , Annamaria Porreca 5 , Massimo Massaia 6 , Benedetto Bruno 7 , Alessandra Borchiellini 1
Affiliation
The introduction Caplacizumab in the management of Immune thrombotic thrombocytopenic purpura (iTTP) has raised different questions, considering its cost-efficacy and the optimal immunosuppressive ...
中文翻译：
ADAMTS13 免疫性血栓性血小板减少性紫癜的自身抗体和护理负担：新证据和未来意义
考虑到其成本效益和最佳免疫抑制药物，Caplacizumab 在免疫血栓性血小板减少性紫癜 (iTTP) 管理中的介绍引发了不同的问题。
更新日期：2022-09-21
中文翻译：
ADAMTS13 免疫性血栓性血小板减少性紫癜的自身抗体和护理负担：新证据和未来意义
考虑到其成本效益和最佳免疫抑制药物，Caplacizumab 在免疫血栓性血小板减少性紫癜 (iTTP) 管理中的介绍引发了不同的问题。
京公网安备 11010802027423号